JP2014526244A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014526244A5 JP2014526244A5 JP2014529143A JP2014529143A JP2014526244A5 JP 2014526244 A5 JP2014526244 A5 JP 2014526244A5 JP 2014529143 A JP2014529143 A JP 2014529143A JP 2014529143 A JP2014529143 A JP 2014529143A JP 2014526244 A5 JP2014526244 A5 JP 2014526244A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- antigen
- cell population
- party
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 71
- 238000000034 method Methods 0.000 claims 36
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 11
- 239000000427 antigen Substances 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 210000004443 dendritic cell Anatomy 0.000 claims 10
- 102000003812 Interleukin-15 Human genes 0.000 claims 9
- 102100030703 Interleukin-22 Human genes 0.000 claims 9
- 102100021592 Interleukin-7 Human genes 0.000 claims 9
- 108010002586 Interleukin-7 Proteins 0.000 claims 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims 9
- 238000012258 culturing Methods 0.000 claims 9
- 210000001519 tissue Anatomy 0.000 claims 9
- 230000000779 depleting effect Effects 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 238000002054 transplantation Methods 0.000 claims 7
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 6
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 4
- 208000024908 graft versus host disease Diseases 0.000 claims 4
- 210000001165 lymph node Anatomy 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 3
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 3
- 230000001464 adherent effect Effects 0.000 claims 3
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 3
- 230000010261 cell growth Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000003614 tolerogenic effect Effects 0.000 claims 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 2
- 230000000735 allogeneic effect Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 210000004738 parenchymal cell Anatomy 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims 1
- 102100033467 L-selectin Human genes 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161532172P | 2011-09-08 | 2011-09-08 | |
| US61/532,172 | 2011-09-08 | ||
| PCT/IL2012/050354 WO2013035099A1 (en) | 2011-09-08 | 2012-09-06 | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014526244A JP2014526244A (ja) | 2014-10-06 |
| JP2014526244A5 true JP2014526244A5 (enExample) | 2015-10-29 |
| JP6196620B2 JP6196620B2 (ja) | 2017-09-13 |
Family
ID=47003163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014529143A Active JP6196620B2 (ja) | 2011-09-08 | 2012-09-06 | 抗第三者セントラルメモリーｔ細胞、その作製方法ならびに移植および疾患処置におけるその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20140212398A1 (enExample) |
| EP (1) | EP2753351B1 (enExample) |
| JP (1) | JP6196620B2 (enExample) |
| KR (1) | KR102073901B1 (enExample) |
| CN (1) | CN103930130B (enExample) |
| AU (1) | AU2012305931B2 (enExample) |
| BR (1) | BR112014005355B1 (enExample) |
| CA (1) | CA2848121C (enExample) |
| ES (1) | ES2640813T3 (enExample) |
| MX (1) | MX351226B (enExample) |
| RU (1) | RU2636503C2 (enExample) |
| SG (1) | SG11201400513PA (enExample) |
| WO (1) | WO2013035099A1 (enExample) |
| ZA (1) | ZA201401993B (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2506311C2 (ru) * | 2008-10-30 | 2014-02-10 | Йеда Рисёрч Энд Девелопмент Ко. Лтд. | Т-клетки центральной памяти против третьей стороны, способы их получения и их применение в трансплантации и лечении заболеваний |
| KR20120059581A (ko) | 2009-08-24 | 2012-06-08 | 윌슨 울프 매뉴팩처링 | 다중 종양 항원 또는 다중 바이러스에 대해 특이성을 갖는 ｃｔｌ주의 생성 |
| JP5977238B2 (ja) | 2010-09-08 | 2016-08-24 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | 抗白血病／リンパ腫処置のための抗第三者セントラルメモリーｔ細胞の使用 |
| BR112014005355B1 (pt) | 2011-09-08 | 2022-03-29 | Yeda Research An Development Co., Ltd | Células t de memória central anti-terceiro, métodos de produção e uso das mesmas em transplante e tratamento de doença |
| JP6081483B2 (ja) | 2011-12-12 | 2017-02-15 | セル・メディカ・リミテッド | Ｔ細胞を増殖させるプロセス |
| GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
| EP2812431B1 (en) | 2012-02-09 | 2019-07-17 | Baylor College Of Medicine | Pepmixes to generate multiviral ctls with broad specificity |
| IL288241B2 (en) * | 2012-06-11 | 2023-10-01 | Wilson Wolf Mfg Corporation | Improved cell culture methods for stress cell therapy |
| AU2016249005B2 (en) * | 2015-04-17 | 2022-06-16 | Novartis Ag | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| CN104946588A (zh) * | 2015-07-07 | 2015-09-30 | 英普乐孚生物技术(上海)有限公司 | 一种抗原特异性t淋巴细胞的分离和高效扩增培养方法 |
| US11179448B2 (en) | 2015-07-16 | 2021-11-23 | Yeda Research And Development Co. Ltd. | Genetically modified anti-third party central memory T cells and use of same in immunotherapy |
| WO2017015427A1 (en) | 2015-07-21 | 2017-01-26 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| IL298359B2 (en) | 2015-09-18 | 2025-12-01 | Baylor College Medicine | Immunogenic antigen identification from a pathogen and correlation to clinical efficacy |
| US10691773B2 (en) | 2015-12-30 | 2020-06-23 | General Electric Company | Cell processing techniques |
| US11472856B2 (en) | 2016-06-13 | 2022-10-18 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
| CN109310746B (zh) * | 2016-06-24 | 2023-12-05 | 麦克马斯特大学 | 过继细胞转移与溶瘤病毒组合疗法 |
| WO2018002924A1 (en) * | 2016-06-27 | 2018-01-04 | Yeda Research And Development Co. Ltd. | Veto cells generated from memory t cells |
| US10751368B2 (en) | 2017-01-18 | 2020-08-25 | Yeda Research And Development Co. Ltd. | Methods of transplantation and disease treatment |
| IL268126B2 (en) * | 2017-01-18 | 2024-02-01 | Yeda Res & Dev | Genetically engineered Veto cells and their uses in immunotherapy |
| US12006512B2 (en) | 2017-01-20 | 2024-06-11 | Kyoto University | Method for producing CD8alpha+beta+ cytotoxic t cells |
| AU2018234827B2 (en) | 2017-03-15 | 2024-04-04 | Orca Biosystems Inc. | Compositions and methods for hematopoietic stem cell transplants |
| KR20210032924A (ko) | 2017-09-05 | 2021-03-25 | 토크 테라퓨틱스, 인코포레이티드 | 치료용 단백질 조성물 및 그의 제조 및 사용 방법 |
| BR112020005552A2 (pt) * | 2017-09-20 | 2020-10-27 | Neximmune, Inc. | composições de células compreendendo células t específicas de antígeno para terapia adotiva |
| CN108165529B (zh) * | 2017-12-28 | 2021-07-16 | 北昊干细胞与再生医学研究院有限公司 | 中枢记忆性t细胞体及其外培养方法 |
| AU2019217363A1 (en) * | 2018-02-06 | 2020-08-20 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Closed-system manufacturing process for CAR-T cells |
| EP3809983B1 (en) | 2018-06-22 | 2025-08-27 | Mayo Foundation for Medical Education and Research | Methods and materials for improving arteriovenous fistula maturation and maintaining arteriovenous fistula functionality |
| US20210283185A1 (en) * | 2018-07-06 | 2021-09-16 | Mayo Foundation For Medical Education And Research | Methods and materials for improving transplant outcomes |
| KR102897600B1 (ko) * | 2018-08-10 | 2025-12-09 | 주식회사 유틸렉스 | 암항원 특이적 세포독성 t세포 |
| CN109628396B (zh) * | 2019-01-24 | 2021-03-26 | 清华大学 | 记忆性淋巴细胞群在肝癌治疗中的应用 |
| JP2022543139A (ja) * | 2019-08-06 | 2022-10-07 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッド | ハプロタイプ一致幹細胞移植における抗ウイルスセントラルメモリーｃｄ８＋ベト細胞 |
| IL292722A (en) * | 2019-11-05 | 2022-07-01 | Yeda res & development co ltd | Use of veto cells in treatment of t cell mediated autoimmune diseases |
| CA3160296A1 (en) * | 2019-11-05 | 2021-05-14 | Yeda Research And Development Co. Ltd. | Use of veto cells for the treatment of sickle cell disease |
| EP4151723A4 (en) * | 2020-05-13 | 2024-06-19 | Agc Inc. | METHOD FOR PRODUCING PROFESSIONAL HUMAN ANTIGEN-PRESENTING CELLS |
| CN116322717A (zh) * | 2020-08-11 | 2023-06-23 | 耶达研究及发展有限公司 | 否决car-t细胞 |
| CN116083359A (zh) * | 2021-11-05 | 2023-05-09 | 瑞创生物技术有限公司 | 一种体外大规模扩增富含Tscm和Tcm的双阴性T细胞的方法 |
| US20230227780A1 (en) * | 2022-01-20 | 2023-07-20 | 3T Biosciences, Inc. | T cell receptor (tcr) compositions and methods for optimizing antigen reactive t-cells |
| US12584107B2 (en) | 2022-01-20 | 2026-03-24 | 3T Biosciences, Inc. | T cell receptor (TCR) compositions and methods for optimizing antigen reactive T-cells |
| US20250152710A1 (en) * | 2022-02-08 | 2025-05-15 | James L. Riley | Modified primary immune cells for induction or enhancement of immunotherapy |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| AU3066599A (en) | 1998-03-03 | 1999-10-18 | University Of Southern California | Use of cytokines and mitogens to inhibit graft versus host disease |
| US6803036B1 (en) | 1998-03-03 | 2004-10-12 | University Of Southern California | Use of cytokines, cells and mitogens to inhibit graft versus host disease |
| WO2000039294A1 (en) | 1998-12-24 | 2000-07-06 | Novartis Ag | Porcine cells incapable of expressing cd40 antigen, for xenotransplantation |
| US6544506B2 (en) | 2000-01-05 | 2003-04-08 | Yeda Research & Development Co. Ltd. | Veto cells effective in preventing graft rejection and devoid of graft versus host potential |
| AU5340001A (en) * | 2000-04-11 | 2001-10-23 | Univ Southern California | A method to prevent graft rejection using tgf-beta to induce t suppressor cells |
| US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| SI1935427T1 (en) | 2000-07-03 | 2018-05-31 | Bristol-Myers Squibb Company | USE OF HEATED CTLA4 MUTANT MOLECULES |
| US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
| EP1337152A4 (en) * | 2000-11-30 | 2004-08-11 | Yeda Res & Dev | METHODS OF USING CULTURED T CELLS THAT DO NOT INDUCE HOST Graft Reaction (GVHD) TO TREAT DISEASE |
| EP1241249A1 (en) * | 2001-03-12 | 2002-09-18 | Gerold Schuler | CD4+CD25+regulatory T cells from human blood |
| PL204899B1 (pl) | 2001-05-23 | 2010-02-26 | Bristol Myers Squibb Co | Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4 |
| US20030147859A1 (en) | 2001-06-18 | 2003-08-07 | Yair Reisner | Methods of utilizing cultured hematopoietic progenitor cells for inducing immunological tolerance |
| US20040136972A1 (en) | 2001-09-07 | 2004-07-15 | Yeda Research And Development Co. Ltd. | Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| CA2486621A1 (en) | 2002-05-22 | 2003-12-04 | The Cleveland Clinic Foundation | Induction and maintenance of tolerance to composite tissue allografts |
| IL165425A0 (en) | 2004-11-28 | 2006-01-15 | Yeda Res & Dev | Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues |
| NZ545314A (en) | 2003-08-04 | 2009-03-31 | Bristol Myers Squibb Co | Methods for treating cardiovascular disease using a soluble CTLA4 molecule |
| EP1708737A2 (en) | 2004-01-15 | 2006-10-11 | Novo Nordisk A/S | Use of interleukin-21 for the treatment of autoimmune diseases and allograft rejection |
| CA2560919A1 (en) | 2004-03-26 | 2005-10-06 | Pfizer Products Inc. | Uses of anti-ctla-4 antibodies |
| WO2006041763A1 (en) | 2004-10-04 | 2006-04-20 | Novartis Ag | Renin inhibitors for treating transplantation induced diseases |
| ES2601896T3 (es) * | 2004-11-24 | 2017-02-16 | Fred Hutchinson Cancer Research Center | Procedimientos de uso de la IL-21 en la inmunoterapia adoptiva y la identificación de antígenos tumorales |
| SI1868635T1 (sl) | 2005-04-06 | 2017-07-31 | Bristol-Myers Squibb Company | Postopki za zdravljenje imunskih motenj, povezanih s transplantacijo presadkov s topnimi mutiranimi CTLA4 molekulami |
| EP2514315A3 (en) * | 2005-08-24 | 2012-11-07 | Yeda Research and Development Co. Ltd. | Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance |
| GB0605217D0 (en) | 2006-03-15 | 2006-04-26 | Novartis Ag | Method and compositions for assessing acute rejection |
| GB0606776D0 (en) | 2006-04-03 | 2006-05-10 | Novartis Pharma Ag | Predictive biomarkers for chronic allograft nephropathy |
| US20080131415A1 (en) | 2006-11-30 | 2008-06-05 | Riddell Stanley R | Adoptive transfer of cd8 + t cell clones derived from central memory cells |
| US20100254958A1 (en) | 2007-10-24 | 2010-10-07 | Anne Letsch | Antigen-Specific T-Cell Preparations from Bone Marrow |
| US8200915B2 (en) | 2008-08-22 | 2012-06-12 | Cadence Design Systems, Inc. | Management of very large streaming data sets for efficient writes and reads to and from persistent storage |
| RU2506311C2 (ru) * | 2008-10-30 | 2014-02-10 | Йеда Рисёрч Энд Девелопмент Ко. Лтд. | Т-клетки центральной памяти против третьей стороны, способы их получения и их применение в трансплантации и лечении заболеваний |
| CN102597222B (zh) | 2009-10-27 | 2015-07-15 | 因缪尼卡姆股份公司 | 用于增殖抗原特异性t细胞的方法 |
| WO2011140170A1 (en) | 2010-05-04 | 2011-11-10 | Yeda Research And Development Co. Ltd. | Immunotherapy using redirected allogeneic cells |
| JP2013540731A (ja) | 2010-09-08 | 2013-11-07 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | 安定かつ長期間の生着のための免疫抑制薬物組合せ |
| JP5977238B2 (ja) | 2010-09-08 | 2016-08-24 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | 抗白血病／リンパ腫処置のための抗第三者セントラルメモリーｔ細胞の使用 |
| US9987308B2 (en) | 2011-03-23 | 2018-06-05 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| KR20140041505A (ko) | 2011-04-29 | 2014-04-04 | 셀렉타 바이오사이언시즈, 인크. | 조절 b 세포 유도를 위한 관용원성 합성 나노운반체 |
| BR112014005355B1 (pt) | 2011-09-08 | 2022-03-29 | Yeda Research An Development Co., Ltd | Células t de memória central anti-terceiro, métodos de produção e uso das mesmas em transplante e tratamento de doença |
| EP3034087B1 (en) | 2011-12-08 | 2018-03-14 | Yeda Research and Development Co. Ltd. | Mammalian fetal pulmonary cells and therapeutic use of same |
| KR20140105848A (ko) | 2011-12-22 | 2014-09-02 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | Ｔ/ｂ 세포 제거를 위한 특정 프로토콜을 이용하는, 안정하고 장기적인 생착을 위한 병용 치료법 |
| PL3824905T3 (pl) | 2012-08-20 | 2025-05-05 | Fred Hutchinson Cancer Center | Sposób i kompozycje do immunoterapii komórkowej |
| WO2014039044A1 (en) | 2012-09-06 | 2014-03-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing t memory stem cell populations |
| EP3763810A3 (en) | 2012-10-10 | 2021-07-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| US9499855B2 (en) | 2013-03-14 | 2016-11-22 | Elwha Llc | Compositions, methods, and computer systems related to making and administering modified T cells |
| CA2907397C (en) | 2013-03-15 | 2022-11-22 | Anthrogenesis Corporation | Modified t lymphocytes |
| WO2014165707A2 (en) | 2013-04-03 | 2014-10-09 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
| DK3148579T3 (da) | 2014-05-28 | 2021-03-08 | Agenus Inc | Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf |
| MX389823B (es) | 2014-10-27 | 2025-03-20 | Fred Hutchinson Cancer Center | Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva. |
| KR20170075013A (ko) | 2014-10-31 | 2017-06-30 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Cart 세포에서 유전자 발현의 변경 및 그의 용도 |
| IL255887B (en) | 2015-05-28 | 2022-09-01 | Kite Pharma Inc | Methods for training patients for t-cell therapy |
| US11179448B2 (en) | 2015-07-16 | 2021-11-23 | Yeda Research And Development Co. Ltd. | Genetically modified anti-third party central memory T cells and use of same in immunotherapy |
| MX2018007295A (es) | 2016-01-11 | 2019-03-28 | Armo Biosciences Inc | Interleucina 10 en la produccion de linfocitos t cd8+especificos para el antigeno y metodos de uso de estos. |
| CN109475581A (zh) | 2016-05-22 | 2019-03-15 | 耶达研究及发展有限公司 | 为了移植及诱导耐受性而使用肺细胞的方法 |
| WO2018002924A1 (en) | 2016-06-27 | 2018-01-04 | Yeda Research And Development Co. Ltd. | Veto cells generated from memory t cells |
| IL268126B2 (en) | 2017-01-18 | 2024-02-01 | Yeda Res & Dev | Genetically engineered Veto cells and their uses in immunotherapy |
| US10751368B2 (en) | 2017-01-18 | 2020-08-25 | Yeda Research And Development Co. Ltd. | Methods of transplantation and disease treatment |
-
2012
- 2012-09-06 BR BR112014005355-3A patent/BR112014005355B1/pt active IP Right Grant
- 2012-09-06 SG SG11201400513PA patent/SG11201400513PA/en unknown
- 2012-09-06 US US14/343,053 patent/US20140212398A1/en not_active Abandoned
- 2012-09-06 CN CN201280054739.XA patent/CN103930130B/zh active Active
- 2012-09-06 MX MX2014002771A patent/MX351226B/es active IP Right Grant
- 2012-09-06 ES ES12769743.1T patent/ES2640813T3/es active Active
- 2012-09-06 JP JP2014529143A patent/JP6196620B2/ja active Active
- 2012-09-06 AU AU2012305931A patent/AU2012305931B2/en active Active
- 2012-09-06 RU RU2014110897A patent/RU2636503C2/ru active
- 2012-09-06 CA CA2848121A patent/CA2848121C/en active Active
- 2012-09-06 KR KR1020147009267A patent/KR102073901B1/ko active Active
- 2012-09-06 WO PCT/IL2012/050354 patent/WO2013035099A1/en not_active Ceased
- 2012-09-06 EP EP12769743.1A patent/EP2753351B1/en active Active
-
2014
- 2014-03-19 ZA ZA2014/01993A patent/ZA201401993B/en unknown
-
2017
- 2017-11-29 US US15/825,275 patent/US11324777B2/en active Active
-
2022
- 2022-05-03 US US17/735,146 patent/US12133866B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014110897A (ru) | Т-клетки центральной памяти против третьей стороны, способы их получения и их применение в трансплантации и лечении заболеваний | |
| RU2011121630A (ru) | Т-клетки центральной памяти против третьей стороны, способы их получения и их применение в трансплантации и лечении заболеваний | |
| JP2013537187A5 (enExample) | ||
| EP2613801B1 (en) | Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment | |
| JP2019520823A5 (enExample) | ||
| WO2012146702A1 (en) | Methods for preparing accessory cells and uses thereof for preparing activated nk cells | |
| Guan et al. | A strategy to reconstitute immunity without GVHD via adoptive allogeneic Tscm therapy | |
| RU2019101826A (ru) | Вето-клетки, полученные из т-клеток памяти | |
| ES2472452B1 (es) | Procedimiento para la selección de linfocitos T antígeno-específicos mediante la identificación de dobletes. | |
| Vianello et al. | Generation of a tissue-engineered thymic organoid | |
| Sattler et al. | GARP as a Tool to Identify Antigen-Specific Human Tregs.: Abstract# B1144 | |
| NZ622749B2 (en) | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment | |
| HK1187528B (en) | Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment | |
| HK1200099B (en) | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |